Meningococcal group B vaccine (colibacillus)(Beijing Zhifei Lvzhu Biopharmaceutical)

重组B群脑膜炎球菌疫苗（大肠杆菌）（北京智飞绿竹）

Report date: 2024/03/19 20:00:40

Base Information

Drug NameMeningococcal group B vaccine (colibacillus)(Beijing Zhifei Lvzhu Biopharmaceutical)
Drug Alias NameRecombinant Meningococcal Group B Vaccine (E. Coli)(Beijing Zhifei Lvzhu Biopharmaceutical)Recombinant Meningococcal Group B Vaccine (E.Coli)(Beijing Zhifei Lvzhu Biopharmaceutical)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Biological material > Bacterial vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMeningococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Zhifei Lvzhu Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Zhifei Lvzhu Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMeningococcal Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A